N1165
吡莫尼唑
≥98% (HPLC), 2-nitroimidazole hypoxia marker, powder
别名:
NSC 380540, PD 126675, Ro 03-8799;, α-[（2-硝基-1H-咪唑-1-基）甲基]-1-哌啶乙醇, α-（（2-硝基咪唑-1-基）甲基）-1-哌啶乙醇;
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C11H18N4O3
化学文摘社编号:
分子量:
254.29
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
吡莫尼唑, ≥98% (HPLC)
color
yellow
SMILES string
OC(CN1CCCCC1)Cn2ccnc2[N+]([O-])=O
InChI key
WVWOOAYQYLJEFD-UHFFFAOYSA-N
InChI
1S/C11H18N4O3/c16-10(8-13-5-2-1-3-6-13)9-14-7-4-12-11(14)15(17)18/h4,7,10,16H,1-3,5-6,8-9H2
assay
≥98% (HPLC)
form
powder
solubility
DMSO: >20 mg/mL
storage temp.
2-8°C
Quality Level
相关类别
Biochem/physiol Actions
吡莫尼唑是一种高效且无毒的外源性2-硝基咪唑缺氧标志物。
吡莫尼唑是一种高效且无毒的外源性2-硝基咪唑缺氧标志物。吡莫尼唑与蛋白质、肽和氨基酸中的巯基形成加合物。
吡莫尼唑在2位有一个硝基和一个咪唑环。吡莫尼唑经历还原，在缺氧细胞中被激活。
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Yong Chen et al.
Disease models & mechanisms, 12(12) (2019-11-11)
Major risk factors for necrotizing enterocolitis (NEC) are formula feeding and prematurity; however, their pathogenic mechanisms are unknown. Here, we found that insufficient arginine/nitric oxide synthesis limits blood flow in the intestinal microvasculature, leading to hypoxia, mucosal damage and NEC
Lena-Christin Conradi et al.
Angiogenesis, 20(4), 599-613 (2017-09-07)
Blockade of the glycolytic activator PFKFB3 in cancer cells (using a maximum tolerable dose of 70 mg/kg of the PFKFB3 blocker 3PO) inhibits tumor growth in preclinical models and is currently being tested as a novel anticancer treatment in phase I
Hypoxia Studies with Pimonidazole in vivo
Aguilera KY and Brekken RA
Bio-protocol, 4(19) (2014)
Esther A Kleibeuker et al.
Oncotarget, 7(47), 76613-76627 (2016-10-27)
The extent of tumor oxygenation is an important factor contributing to the efficacy of radiation therapy (RTx). Interestingly, several preclinical studies have shown benefit of combining RTx with drugs that inhibit tumor blood vessel growth, i.e. angiostatic therapy. Recent findings
Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma
Varia MA, et al.
Gynecologic Oncology, 71(2), 270-277 (1998)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持